Mayinglong Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 5/6
Mayinglong Pharmaceutical Group has a total shareholder equity of CN¥4.1B and total debt of CN¥164.5M, which brings its debt-to-equity ratio to 4%. Its total assets and total liabilities are CN¥5.1B and CN¥994.3M respectively. Mayinglong Pharmaceutical Group's EBIT is CN¥518.0M making its interest coverage ratio -6.5. It has cash and short-term investments of CN¥3.0B.
Key information
4.0%
Debt to equity ratio
CN¥164.47m
Debt
| Interest coverage ratio | -6.5x |
| Cash | CN¥3.01b |
| Equity | CN¥4.13b |
| Total liabilities | CN¥994.31m |
| Total assets | CN¥5.12b |
Recent financial health updates
Recent updates
Estimating The Intrinsic Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)
Oct 01
What Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) P/E Is Not Telling You
Aug 19Mayinglong Pharmaceutical Group's (SHSE:600993) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 24Mayinglong Pharmaceutical Group (SHSE:600993) Has A Rock Solid Balance Sheet
Jun 19Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Price Is Right But Growth Is Lacking After Shares Rocket 26%
May 07Investors Don't See Light At End Of Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Tunnel
Mar 22Financial Position Analysis
Short Term Liabilities: 600993's short term assets (CN¥4.0B) exceed its short term liabilities (CN¥834.8M).
Long Term Liabilities: 600993's short term assets (CN¥4.0B) exceed its long term liabilities (CN¥159.5M).
Debt to Equity History and Analysis
Debt Level: 600993 has more cash than its total debt.
Reducing Debt: 600993's debt to equity ratio has increased from 1.5% to 4% over the past 5 years.
Debt Coverage: 600993's debt is well covered by operating cash flow (513.7%).
Interest Coverage: 600993 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 06:48 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mayinglong Pharmaceutical Group Co., Ltd. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jun Liu | Changjiang Securities Co. LTD. |
| Ling Bo Tu | China Minzu Securities |
| Bing Zhao | China Renaissance Securities |